1 / 11

Endocrinology

Endocrinology. Acromegaly. Acromegaly. Very rare Prevalence in the order of 1 in 200,000 Usually diagnosed between age 40 and 60 No difference in gender susceptibility Insidious onset. Pathogenesis. Most commonly caused by pituitary adenoma Increased secretion of growth hormone

raleigh
Télécharger la présentation

Endocrinology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Endocrinology Acromegaly

  2. Acromegaly • Very rare • Prevalence in the order of 1 in 200,000 • Usually diagnosed between age 40 and 60 • No difference in gender susceptibility • Insidious onset

  3. Pathogenesis • Most commonly caused by pituitary adenoma • Increased secretion of growth hormone • Acts in liver to release IGF-1 (insulin-like growth factor)

  4. So what are the symptoms? • Tumour • Growth hormone • IGF-1

  5. On examination • Characteristic facial appearance: Coarse, Frontal bossing, ↑sinuses, ↑ tongue, Prognathism (jaw protrusion), separation of teeth • Deep voice • Carpal tunnel syndrome • Hand & foot enlargement • Visual fields (bitemporalhemianopia) • Organomegaly: Goitre, Hepatosplenomegaly

  6. Investigations • Glucose tolerance test with measurement of growth hormone level. • (Should be inhibited by glucose) • (Growth hormone secretion is episodic and so a random GH alone is unlikely to be useful) • Evidence of other pituitary involvement • MRI scan to identify adenoma

  7. Management • Surgery: trans-sphenoidaladenomectomy or craniotomy for very large tumours. • Pituitary radiotherapy: useful if tumour is not fully removed and reduces GH progressively over years. • Drugs: • Somatostatin analogues (octreotide, lanreotide) suppress GH in 60% • Dopamine agonists (bromocriptine, cabergoline) lower but rarely normalize GH • GH receptor antagonist (pegvisomant) normalizes IGF-I in >90% of pts.

  8. Bonus marks management Management of: • ↑ Cardiovascular morbidity & mortality – from HTN, impaired GTT (25%), Diabetes Mellitus (10%) • ↑ Cardiac failure (heart muscle disease), ↑IHD, ↑CVD • Obstructive sleep apnoea • Arthropathy (50%) • Osteoporosis • Colorectal cancer Complication of treatment: hypopituitarism

More Related